retatrutide phase 2 type 2 diabetes weight loss 2024 with as compared to currently licenced obesity Retatrutide, a TRIPLE agonist (GLP1,

La obesidad contribuye al desarrollo de la AOS principalmente a travs del exceso de tejido adiposo que rodea la va area superior que puede causar estrechamiento de las vas respiratorias e incrementar su tendencia al colapso durante el sueo3

Unfortunately, the current trend is completely the opposite, with a steady increase in overweight and obesity affecting the youngest, putting them at very high risk of developing a veritable epidemic of cardiometabolic diseases in a few years (see our article on this subject)

Our guide on switching from tirzepatide to retatrutide covers the transition in detail

Sharifi-Rad et al., 2020